PMC9358716_01
Timeline summary with corresponding CT of the different therapeutic lines between February 2016 and November 2021. Baseline chest CT showing (A) a lung mass in the left lower lobe. Best response under afatinib with a partial response (B, thick arrow). Chest CT before osimertinib's beginning (C) and follow-up CT chest with a stable disease as best response (D, arrowhead). Baseline chest CT (E) and contrast-enhanced liver (G) CT before neratinib. At 1 month, early assessment showed a partial response of all lung lesions (F, thin arrow) and liver lesions (H, a target lesion, 29.8 vs. 18.4 mm, in the longest axis). Red arrow and case: the liver's oligoprogression at second CT evaluation under neratinib and a new liver biopsy was done. Immunohistochemistry showed the loss of ErbB2 hyperexpression. CT, computed tomography.
fonc-12-918855-g001.jpg
PMC9358716_01_fonc-12-918855-g001.jpg
f1
The clinical and morphological response was confirmed for 13 months ( Figures 1A, B ). The best morphological response was a stable disease ( Figures 1C, D ). Early assessment by CT at 4 weeks showed a partial response (-38%) with a decrease in all pulmonary ( Figures 1E, F ) and liver lesions ( Figures 1G, H ).